%PDF-1.4
%
65 0 obj
<>
endobj
62 0 obj
<>
endobj
117 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2005-07-05T16:27:34Z
2024-03-29T02:22:44-07:00
QuarkXPressª: AdobePS 8.8.0 (301)
2024-03-29T02:22:44-07:00
application/pdf
Heather
2004-690.aug
uuid:cb5f36e0-1dd1-11b2-0a00-550827edca00
uuid:cb5f36e2-1dd1-11b2-0a00-380000000000
endstream
endobj
51 0 obj
<>
endobj
52 0 obj
<>
endobj
66 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 35 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 37 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 39 0 R/Type/Page>>
endobj
23 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 41 0 R/Type/Page>>
endobj
26 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 43 0 R/Type/Page>>
endobj
29 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 45 0 R/Type/Page>>
endobj
139 0 obj
[143 0 R]
endobj
140 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
13.5 787.5 585 -783 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.01601 Tw 10 0 0 10 54 734.8264 Tm
[(prior to their remission. Similarly)64.8 (, when remission was bro-)]TJ
0.1245 Tw 0 -1.2 TD
(ken in 7 of these 12 patients, the recurrent manifestations)Tj
0.0186 Tw T*
(could either be serological only \(3\), minor clinical manifes-)Tj
0.192 Tw T*
(tations \(mucous membrane ulcers in 1 patient\), or major)Tj
-0.0182 Tw T*
[(clinical manifestations \(3\). )17.7 (Therefore the nature of the or)17.7 (gan)]TJ
0.0155 Tw T*
(involvement characterizing disease prior to and after a peri-)Tj
0.1707 Tw T*
(od of remission does not distinguish these patients. Only)Tj
0.045 Tw T*
(careful longterm surveillance of patients will identify those)Tj
-0.0269 Tw T*
(destined to go into remission and similar careful followup of)Tj
0.3309 Tw T*
(those in remission will detect relapse of their disease.)Tj
0.14059 Tw T*
(Obviously newer treatment strategies are required to alter)Tj
0.02499 Tw T*
(this prognosis.)Tj
0.23711 Tw 1.2 -1.2 Td
[(T)69.9 (o compare incidence/prevalence of remission among)]TJ
-0.0101 Tw -1.2 -1.2 Td
(centers it will be necessary to develop consensus on the def-)Tj
0.0589 Tw T*
(inition of remission and its duration. It is likely that remis-)Tj
-0.02699 Tw T*
(sion will be defined in a number of ways including complete)Tj
0.16341 Tw T*
(clinical and serological remission, clinical remission with)Tj
0.04131 Tw T*
(persistence of serological abnormalities, and either of these)Tj
0.02499 Tw T*
[(with or without therapy)64.8 (. )]TJ
/T1_1 1 Tf
0 Tw 0 -2.4 TD
(REFERENCES)Tj
/T1_0 1 Tf
0.02499 Tw 8 0 0 8 61 484.8264 Tm
[(1.)-875.1 (Urowitz MB, Bookman )54.8 (AAM, Koehler BE, Gordon DA, Smythe)]TJ
1.675 -1.25 Td
[(HA, Ogryzlo MA. )17.7 (The bimodal mortality pattern of systemic lupus)]TJ
0 -1.25 TD
[(erythematosus. )54.9 (Am J Med 1976;60:221-5.)]TJ
-1.675 -1.25 Td
[(2.)-875.1 (Gladman DD, Urowitz MB. Morbidity in systemic lupus )]TJ
1.675 -1.25 Td
(erythematosus. J Rheumatol 1987;14 Suppl 13:223-6.)Tj
-1.675 -1.25 Td
[(3.)-875.1 (Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality)]TJ
1.675 -1.25 Td
(studies in systemic lupus erythematosus. Results from a single )Tj
T*
[(center)54.8 (. I. Causes of death. J Rheumatol 1995;22:1259-64.)]TJ
-1.675 -1.25 Td
[(4.)-875.1 (Gladman DD, Iba\226ez D, Urowitz MB. Systemic lupus )]TJ
1.675 -1.25 Td
(erythematosus disease activity index 2000. J Rheumatol)Tj
0 Tc 0 Tw T*
(2000;29:288-91.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(5.)-875.1 (Gladman DD, Goldsmith CH, Urowitz MB, et al. Crosscultural )]TJ
1.675 -1.25 Td
(validation and reliability of 3 disease activity indices in systemic)Tj
T*
[(lupus erythematosus. J Rheumatol 1992;19:608-1)36.8 (1.)]TJ
-1.675 -1.25 Td
[(6.)-875.1 (Hay EM, Bacon P)91.7 (A, Gordon C, et al. )17.7 (The BILAG index: a reliable)]TJ
1.675 -1.25 Td
(and valid instrument for measuring clinical disease activity in )Tj
T*
(systemic lupus erythematosus. Q J Med 1993;86:447-58.)Tj
-1.675 -1.25 Td
[(7.)-875.1 (Gladman DD, Goldsmith CH, Urowitz MB, et al. Sensitivity to)]TJ
1.675 -1.25 Td
(change of 3 systemic lupus erythematosus disease activity indices:)Tj
T*
(international validation. J Rheumatol 1994;21:1468-71.)Tj
-1.675 -1.25 Td
[(8.)-875.1 (Gladman DD, Urowitz MB, Goldsmith CH, et al. )17.7 (The reliability of)]TJ
1.675 -1.25 Td
(the Systemic Lupus International Collaborating Clinics/American)Tj
T*
(College of Rheumatology Damage Index in patients with systemic)Tj
T*
[(lupus erythematosus. )54.8 (Arthritis Rheum 1997;40:809-13. )]TJ
-1.675 -1.25 Td
[(9.)-875.1 (T)69.9 (ozman ECS, Urowitz MB, Gladman DD. Prolonged complete)]TJ
1.675 -1.25 Td
[(remission in previously severe SLE. )54.8 (Ann Rheum Dis )]TJ
0 Tc 0 Tw T*
(1982;41:39-40.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(10.)-875.1 (Drenkard C, )17.7 (V)59.8 (illa )54.8 (AR, Garcia-Padilla C, Perez-V)110.7 (azquez ME,)]TJ
2.175 -1.25 Td
(Alarcon-Segovia D. Remission of systemic lupus erythematosus.)Tj
T*
(Medicine Baltimore 1996;75:88-98.)Tj
30.8619 67.671 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Formiga F)79.7 (, Moga I, Pac M, Mitjavila F)79.7 (, Rivera )54.8 (A, Pujol R. High)]TJ
2.1381 -1.25 Td
(disease activity at baseline does not prevent a remission in patients)Tj
T*
(with systemic lupus erythematosus. Rheumatology Oxford)Tj
0 Tc 0 Tw T*
(1999;38:724-7. )Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(12.)-875.1 (Heller CA, Schur PH. Serological and clinical remission in )]TJ
2.175 -1.25 Td
(systemic lupus erythematosus. J Rheumatol 1985;12:916-8. )Tj
-2.175 -1.25 Td
[(13.)-875.1 (Schneider M. Response and remission criteria for clinical trials in)]TJ
2.175 -1.25 Td
(lupus: what can we learn from other diseases? Lupus )Tj
0 Tc 0 Tw T*
(1999;8:627-31. )Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(14.)-875.1 (Ravirajan CT)73.9 (, Rowse L, MacGowan JR, Isenber)17.7 (g DA. )54.8 (An analysis)]TJ
2.175 -1.25 Td
(of clinical disease activity and nephritis-associated serum )Tj
T*
(autoantibody profiles in patients with systemic lupus )Tj
T*
[(erythematosus: a cross-sectional study)64.8 (. Rheumatology Oxford)]TJ
0 Tc 0 Tw T*
(2001;40:1405-12.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(15.)-875.1 (Gladman DD, Urowitz MB, Keystone EC. Serologically active clin-)]TJ
2.175 -1.25 Td
(ically quiescent systemic lupus erythematosus: discordance)Tj
T*
[(between clinical and serologic features. )54.8 (Am J Med 1979;66:210-5. )]TJ
-2.175 -1.25 Td
[(16.)-875.1 (T)69.9 (sakonas E, Joseph L, Esdaile JM, et al. )54.8 (A)-220.1 (long-term study of)]TJ
2.175 -1.25 Td
(hydroxychloroquine withdrawal on exacerbations in systemic lupus)Tj
T*
[(erythematosus. )17.7 (The Canadian Hydroxychloroquine Study Group.)]TJ
0 Tc T*
(Lupus 1998;7:80-5.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(17.)-875.1 (Lee P)110.7 (, Urowitz MB, Bookman )54.8 (AAM, et al. Systemic lupus )]TJ
2.175 -1.25 Td
[(erythematosus. )54.8 (A)-220.1 (review of 1)36.8 (10 patients with reference to nephritis,)]TJ
T*
(the nervous system, infections, aseptic necrosis and prognosis. )Tj
0 Tc T*
(Q J Med 1977;46:1-32.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(18.)-875.1 (Iba\226ez D, Urowitz MB, Gladman DD. Summarizing disease )]TJ
2.175 -1.25 Td
[(features over time: I. )54.8 (Adjusted mean SLEDAI derivation and )]TJ
T*
(application to an index of disease activity in lupus. J Rheumatol)Tj
0 Tc T*
(2003; 30:1977-82.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(19.)-875.1 (Dubois EL, )17.7 (T)35 (u)0.1 (f)17.7 (fanelli DL. Clinical manifestations of systemic)]TJ
2.175 -1.25 Td
(lupus erythematosus: Computer analysis of 520 cases. JAMA)Tj
0 Tc 0 Tw T*
[(1964;190:104-1)36.9 (1.)]TJ
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(20.)-875.1 (Hodis HN, Quismorio FP)-238.2 (Jr)39.7 (, )17.7 (W)39.8 (ickham E, Blankenhorn DH. )17.7 (The)]TJ
2.175 -1.25 Td
[(lipid, lipoprotein, and apolipoprotein ef)17.7 (fects of hydroxychloroquine)]TJ
T*
(in patients with systemic lupus erythematosus. J Rheumatol 1993;)Tj
0 Tc 0 Tw T*
(20:661-5.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(21.)-875.1 (Petri M, Lakatta C, Magder L, Goldman D. Ef)17.7 (fect of prednisone)]TJ
2.175 -1.25 Td
(and hydroxychloroquine on coronary artery disease risk factors in)Tj
T*
[(systemic lupus erythematosus: a longitudinal data analysis. )54.8 (Am )]TJ
0 Tc T*
(J Med 1994;96:254-9.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(22.)-875.1 (Rahman P)110.7 (, Gladman DD, Urowitz MB, )36.8 (Y)110.8 (uen K, Hallett D, Bruce)]TJ
2.175 -1.25 Td
[(IN. )17.7 (The cholesterol lowering ef)17.7 (fect of antimalarial drugs is)]TJ
T*
(enhanced in patients with lupus taking corticosteroid drugs. )Tj
T*
(J Rheumatol 1999;26:325-30.)Tj
-2.175 -1.25 Td
[(23.)-875.1 (W)79.9 (allace DJ, Metzger )54.8 (AL, Stecher )17.7 (VJ, )17.7 (T)35 (urnbull BA, Kern P)91.7 (A.)]TJ
2.175 -1.25 Td
[(Cholesterol-lowering ef)17.7 (fect of hydroxychloroquine in patients with)]TJ
T*
[(rheumatic disease: reversal of deleterious ef)17.7 (fects of steroids on)]TJ
T*
[(lipids. )54.8 (Am J Med 1990;89:322-6.)]TJ
-2.175 -1.25 Td
[(24.)-875.1 (Petri M. Hydroxychloroquine use in the Baltimore Lupus Cohort:)]TJ
2.175 -1.25 Td
[(ef)17.7 (fects on lipids, glucose and thrombosis. Lupus 1996;5 Suppl)]TJ
0 Tw T*
(1:S16-22.)Tj
0.02499 Tw -2.175 -1.25 Td
[(25.)-875.1 (Erkan D, )36.8 (Y)99.8 (azici )36.8 (Y)128.9 (, Peterson MG, Sammaritano L, Lockshin MD. )54.8 (A)]TJ
2.175 -1.25 Td
(cross-sectional study of clinical thrombotic risk factors and )Tj
T*
(preventive treatments in antiphospholipid syndrome. Rheumatology)Tj
T*
(Oxford 2002;41:924-9.)Tj
ET
0 0 0 1 K
53.964 76.5 m
558.972 76.5 l
S
0 0 0 0 k
52.822 69.665 64.178 -15.665 re
f*
BT
0 0 0 1 k
/T1_2 1 Tf
0 Tc 0 Tw 8 0 0 8 53.8216 56.7343 Tm
(1472)Tj
ET
0 0 0 0 k
356 69.665 203 -15.665 re
f*
BT
0 0 0 1 k
/T1_2 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 424.3613 56.7343 Tm
(The Journal of Rheumatology 2005; 32:8)Tj
ET
0 0 0 0 k
/GS0 gs
104.631 81.583 407.5 -10.833 re
f*
0.5 w
/GS1 gs
104.631 81.583 407.5 -10.833 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_3 8 Tf
108.828 74 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2005. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
45 0 obj
<>stream
8;Z\7=`sm%#ikn#j>pRY,_Ue_Csr7R%;GF&`*j6E\F,FV,I:$)%fAM?s8G-@GE4uD
p;?_%jjU!Ba6;mZJ!&?FPelDMb+'RAeG-M]m'k2N^n1!9-(7Up?`GiUjhn!C(&H5,K7[R>nSbRk&`Se)Si/&$WRblZO=\Yjn+VRQ2:r
lKgS(VjI6X,B(mO7>hb>EgM^^7(4]o4+skpZbS5h'/sm3be%\`Si&:QW6PUFXV*'C
_>6miG;\R#;Pi4ZqH.r>Jn!D,Km4p5'e6(+^h,+*;1K5!A2L`L1LFNbVdh7f
.:m2)Icl.0q1F4$-Q,^LXt$[q2dP%`ASW)8/-il\WMd8!"Igp[;I)T,P]tosYWhoM
0[UaJRb)-:^B1@;(\JQsA__utR_FPnklGKoc.+pAKBC.(GR:oe96Q70jE'HiC(?7Q
]36A+]Ng.HGe=T_WWHTp7NPhl880JDmFtO001fP*N%`o#F*qGCAp\^@Y?pG&_k_.Q
R^7s&c@>a)!0Ylh##&fsBut%@/KQ8bKmaMqgYcV5Qn*Rjg4%Pu8W7bW?pX)gI,V%W
E(ufO:"M?hVWFu5,7R^u+[j>[X_lh?%4'SaaKQJC"0PKS?MGhH7Gr_jb*i)AMH9tA
7ES\!9^.?%Y;,uICi>@A-b?6@p=NmTh5k$`-f+9ab%l(YR-p#*3$4XEf)Y(tdlm~>
endstream
endobj
49 0 obj
[/Indexed/DeviceRGB 255 48 0 R]
endobj
48 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
80 0 obj
<>
endobj
32 0 obj
<>
endobj
68 0 obj
<>
endobj
104 0 obj
<>
endobj
122 0 obj
<>
endobj
69 0 obj
<>
endobj
95 0 obj
<>stream
HtUiTWf.JW85KmYFAZ11b@-!u2zp(J4c26-r)L93s;wd!Ɇ/;gb>Yg0M5/G8\qŸ;7 jV/]p뼿e5AdJ֠)AA&-i@!8tzȤ!{:dCxCNXiN%)q`ҦBXR9,D:S}cAoBIK֚CXbH4ꄰ6%~$%y[Yך:_}? 41̉r#Fzt${yq "r$;qMmv
q8#Ov^|عHF+/[}. ..vM^;lܰa?Uy$z<5˦^~@mý_c"w7>}|.g2hPtћ`3m3W.^Vқrm$.©0Cُ85N 20vOƃ8X}i/,*n#XA,ٝ[2dYI.-sX&D%dJG@Tȡ>e@,&H|ˎ\|Ɲnl:jON6u
j^Āℬx 91/<Y$cxv#UJN&8cft[0!q*M9C} KPo>)[QTvbYQVvtfɻym5qWaNQ>`~Ƹ~*=[&: